CellerateRX(R) Reports Significant Second Quarter and Annual Sales Increase
CellerateRX, which has widely been used for treatment of podiatric wounds, specifically diabetic ulcers, is now being utilized by other medical practices. These include but are not limited to the treatment of burns, surgical wounds, and dermatological procedures. These additional procedures join the already extensive list of medical conditions CellerateRX has successfully treated. Wound Management Technologies, Inc., attributes the expansion of usage for the activated collagen wound management system, CellerateRX, as a driving force for increased financial results.
Wound Management Technologies, Inc. is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management's primary focus is the distribution of its unique, patented collagen product, CellerateRX®, which is FDA cleared and reimbursable under Medicare Part B. Wound Management has other advanced biotech products in development including a patented resorbable bone wax line that is in late stages of development, as well as a subsidiary focused on technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: http://www.wmgtech.com and http://www.celleraterx.com.
Undiscovered Equities is a leading provider of equity research on high impact oil and gas exploration projects and other aggressive growth investment opportunities. Our services include research analysis on the energy, precious metals, biotech and industrial tech markets, news and financial data, market commentary and the Undiscovered Equities newsletter. Undiscovered Equities' staff of small cap investment professionals are dedicated to providing the investment community with the tools and avenues necessary to identify undiscovered or undervalued stocks, invest their money wisely and build wealth. To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.